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The article by Giles et al. (1) comparing tht; therapeutic effects Of a 
tong-acting angiotensin-converting enzym:: (ACE) inhibitor, lisino- 
pril, with a short-acting agent, captopril, in patients with heart 
failure is most timely as it addresses an issue of growing importance, 
that is, whether the various ACE inhibitors have any significant 
differences in therapeutic action. The increasing number of such 
agents being offered for clinical use urgently requires that such 
randomized comparative studies be undertaken. 
Unfortunately. this article omits much vital information. pre- 
cludingobjective evaluation of its conclusions. First, captopril has a 
peak effect at 2 h, whereas lisinopril has a peak action at 6 to 8 h. 
Therefore, the timing of the exercise testing and the measurement of 
ejection fraction are critical to the evaluation, but no data as to the 
relationship of these assessments to dosing are provided in the 
paper. The primary end point, treadmill exercise testing, was not 
significantly different between the two drugs and is acknowledged as 
such. However, neither was the increase in ejection fraction when 
all the patient groups were analyzed (Fig. 4). It is only when the 
subgroup of patients with an ejection fraction ~3.5% is tested that a 
significant difference emerges between the two drugs (Fig. 4). This 
figure is almost incomprehensible because the magnitude of differ- 
ence in this subgroup is identical as for all patients: there are 18 
patients fewer, yet the results are statistically significant for the 
subgroup but not for the total group. Whatever the statistics, one 
would like to know whether the subgroups in which significant 
differences were shown, ejection fraction 135%, for instance, were 
arrived at by retrospective subgroup analysis or had been prospec- 
tively defined for some reason. This is highly relevant to the reliance 
that can be put on the findings. There also does not appear to be any 
difference in the softer end points such as New York Heart 
Association class, Yale scales or cardiothoracic ratio on the chest 
radiograph. Likewise, there is no significant difference in adverse 
effects. 
Our impression of this report is that it is a negative study. It 
shows no important differences between the two drugs in the 
therapy of heart failure as defined by the authors. There are several 
methodologic defects that may have precluded a difference from 
being demonstrated. 
It certainly provides no basis for the conclusions in the accom- 
panying editorial by Jessup (21 that the study is “the first such 
comparison to show that clinical benefits occur more often with a 
specific ACE inhibitor.” They may well do so, but the present study 
is inconclusive on this vital point. More pertinent is her final 
comment: “unfortunately. until more research is accomplished, the 
choice of an ACE inhibitor for the patient with heart failure rests 
more on whimsy than on wisdom.” 
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lkram and White fail to see the differences between the long-acting 
angiotensin-converting enzyme (ACE) inhibitor lisinopril and the 
short-acting ACE inhibitor captopril as found in our comparison trial 
of these drugs in patients with congestive heart failure. 
the differences in efficacy for a long-acting ACE inhibitor (lisinopril) 
versus a short-acting ACE inhibitor (captopril) in the treatment of 
patients with congestive heart failure are evident. The long-acting 
ACE inhibitor is given once daily, whereas the short-acting ACE 
inhibitor requires three times daily dosing. The peak effect of the 
two agents on blood pressure clearly occurs at different times: 
captopril2 h after dosing, versus lisinopril5 or 6 h after dosing (our 
Fig. I). The slow onset of the long-acting ACE inhibitor accompa- 
nied by prolonged and even suppressIon of the adverse cardiovas- 
cular effects of unsustained suppression of the activated renin- 
angiotensin-aldosterone system in patients with congestive heart 
failure, may also be an advantage. On the other hand, the unsus- 
tained suppression of the renin-angiotensin-aldosterone by the 
short-acting ACE inhibitor captopril may produce a roller coaster 
effect of activation and inhibition with resultant hemodynamic 
consequences. Because of restrictions oa scheduling patients for 
ejection fraction and exercise tests. these tests were done within 2 to 
3 h of the dose, which may have favored the short-acting ACE 
inhibitor peak effects. However, the peak changes in blood pressure 
may not be as important as ACE inhibition in tissue systems (I) for 
predicting long-term changes in exercise duration or ejection frac- 
tions. 
The primary end point, treadmill exercise duration, was im- 
proved from baseline for the short-acting and long-acting ACE 
inhibitors. However, exercise duration with the long-acting ACE 
inhibitor was ndi!lerically greater than that with the short-acting 
agent. This numerical difference was statistically significant 
(p 5 0.05) when protocol violators were excluded from the analysis. 
Two subgroups of patients, the elderly group and patients with renal 
impairment, had significantly improved exercise duration with the 
long-acting agent (2). 
For the all-patients-treated analysis, the increase in ejection 
fraction with the long-acting ACE inhibitor was significantly (p < 
0.001) increased from baseline, whereas the short-acting ACE 
inhibitor failed to show this improvement (p = 0.2271). The differ- 
ence between the short-acting and long-acting agents’ effects on 
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shown an improved swviwal rate in patients wi h severe congestive 
hea~fai~ure (5), a ~et~os~ec~~we Sook at t ~b~~~M~ ~~~at~ents with 
a baseline ejection fraction 535% was ~ti~ed as an interesting 
ment of patients with congestive heart failure. 
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